Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. - Khoury K; Meisel JL; Yau C; Rugo HS; Nanda R; Davidian M; Tsiatis B; Chien AJ; Wallace AM; Arora M; Rozenblit M; Hershman DL; et al. (Nature medicine, 2024)